Shares of Perrigo (PRGO) have gained 8.8% over the past four weeks to close the last trading session at $26.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.25 indicates a potential upside of 27.3%.The mean estimate comprises four short-term price targets with a standard deviation of $6.95. While the lowest estimate of $27 indicates a 0.3% increase from the current price ...

Group 1 - The Zacks Rank system focuses on earnings estimates and revisions to identify winning stocks, while also considering trends in value, growth, and momentum [1][2] - Value investing is a preferred strategy for finding strong stocks, relying on traditional analysis of key valuation metrics to identify undervalued stocks [2] - Zacks has developed a Style Scores system to identify stocks with specific traits, particularly in the "Value" category, where stocks with "A" grades and high Zacks Ranks are considered strong value stocks [3] Group 2 - Perrigo (PRGO) is highlighted as a potential value investment, currently holding a Zacks Rank of 2 (Buy) and an A grade for Value [4] - PRGO has a Forward P/E ratio of 8.77, significantly lower than the industry average of 22.45, with its Forward P/E ranging from a high of 10.68 to a low of 7.66 over the past year [4] - The P/S ratio for PRGO is 0.87, compared to the industry's average P/S of 1.38, indicating that PRGO may be undervalued [5] - Overall, PRGO stands out as one of the market's strongest value stocks, supported by its earnings outlook and valuation metrics [6]

Have you evaluated the performance of Perrigo's (PRGO) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this drug company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investor ...

Perrigo (PRGO) reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.During the q ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations & Corporate CommunicationsPatrick Taylor - President & CEOEduardo Bezerra - Executive VP & CFOSarah Whitaker Clemente - Director, HealthcareDaniel Biolsi - Managing Director Conference Call Participants Ethan Brown - Equity Research AnalystSusan Anderson - Managing Director & Senior AnalystKeith Devas - Analyst Operator ladies and gentlemen, and welcome to t ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 ladies and gentlemen, and welcome to the Perrigo Q1 twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/07/2025. I would now like to turn the conference over to Brad Joseph, VP, Global Investor Relations. Please go ahead. Speaker1 Good morning and good afternoon ...

Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this drug company would post earnings of $0.92 per share when it actually produced earnings of $0.93, delivering a surprise of 1.09%.Over the last four quarters, the company has s ...

Q1 2025 Earnings Presentation May 7, 2025 Bradley Joseph VP Investor Relations & Corporate Communications Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or ...

EXHIBIT 99.1 Fiscal Year 2025 Outlook: • The Company widens its fiscal 2025 outlook for reported net sales growth to 0% to 3% from 1% to 3% and organic net sales growth to 1.5% to 4.5% from 2.5% to 4.5%. The Company reaffirms all other 2025 financial targets, including adj. EPS. This outlook includes known impacts from marcroeconomic uncertainty, including tariffs (see "Known Impacts from Macroeconomic Uncertainty" section below for details). (1) See attached Appendix for details. Change in net sales on an ...

Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor DayDelivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC BrandsWidened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS RangeDUBLIN, May 7, 2025 /PRNewswire/ --First Quarter 2025 Highlights: Net sales of $1.04 billion declined ...